Introduction
============

Acute pancreatitis (AP) is the most common complication of endoscopic retrograde cholangiopancretography (ERCP) [@JR1710-1] [@JR1710-2] . Since the time of injury to the pancreas is known in patients undergoing ERCP, several pharmacologic agents have been studied for the prevention of post-ERCP pancreatitis (PEP). Rectal indomethacin has been the only drug thus far associated with a significantly lower risk of PEP if given immediately after ERCP [@JR1710-3] . In addition, prophylactic pancreatic duct stent placement has also been shown to significantly reduce the risk of PEP in high-risk patients [@JR1710-4] .

Fluid therapy has been the mainstay of treating acute pancreatitis for years in the absence of a specific pharmacological therapy [@JR1710-5] . The role of fluids in PEP was first evaluated by Cote et el. in a retrospective study that showed a decreased length of hospital stay in patients who received increased volumes of fluid in the first 24 hours after undergoing ERCP [@JR1710-6] . Following this, two randomized controlled trials have shown a decreased incidence of PEP among average-risk patients with use of lactated Ringerʼs (LR) solution [@JR1710-7] [@JR1710-8] . However, both of these trials assessed the impact of fluid administration over 8 hours after ERCP and, therefore, may lack generalizability to centers who perform ERCP in primarily outpatients and/or cannot keep patients in post-anesthesia recovery areas for long periods of time. These trials also did not evaluate concurrent use of lactated Ringerʼs and rectal indomethacin, which best reflects current clinical practice in most centers [@JR1710-3] . In addition, neither of these trials evaluated high-risk patients. A more recent trial, utilizing a 2 × 2 factorial design, evaluated the combination of LR and rectal indomethacin in high risk patients and found a significant difference, in favor of combination prophylaxis, over a pure placebo arm. Many would question the inclusion of a "pure" placebo arm, where high risk patients did not receive any prophylaxis [@JR1710-9] . This trial was also markedly underpowered and there was no significant difference found between combination prophylaxis and rectal indomethacin alone.

The primary aim of the current study was to evaluate the impact of type and volume of intravenous (IV) fluid administered on the incidence of PEP in high-risk patients through a secondary analysis of the INDIEH trial [@JR1710-10] . The secondary aim was to determine if the type and volume of IV fluid administered reduced the length of hospital stay.

Patients and methods
====================

Study design
------------

The current study is a secondary analysis of a prospective multicenter, double blinded, randomized trial in high risk patients comparing the efficacy of rectal indomethacin versus a combination of topical spray of epinephrine and rectal indomethacin for the prevention of PEP in high-risk patients (INDIEH trial) [@JR1710-10] . The trial was conducted at four tertiary care teaching hospitals, the Johns Hopkins Medical Institutions (United States), Asian Institute of Gastroenterology (India), Postgraduate Institute of Medical Education & Research (India) and Apollo Gleneagles Hospital (India). Informed consent was obtained from each eligible patient prior to ERCP. An independent Data and Safety Monitoring Board (DSMB) including a group of four experts in ERCP, two from the United States and two from India, reviewed the results of the interim analysis of the INDIEH trial as well as adverse events and provided regulatory oversight.

Study procedure
---------------

The INDIEH trial included adult (\> 18 years of age) patients who were randomized to receive either a combination of 100 mg of indomethacin and topical spray of 20 mL of normal saline (indomethacin alone group) or a combination of 100 mg of indomethacin and topical spray of 20 mL of 0.02 % epinephrine (combination group) at the end of ERCP using a web-based central randomization system, REDCap (research electronic data capture). [@JR1710-11] Only high risk patients meeting one major or two minor validated patient or procedural risk factors for developing PEP were included [@JR1710-3] . Patients who underwent planned therapeutic pancreatic stenting and those with suspected sphincter of Oddi dysfunction (SOD) type 3 were excluded from the study.

Demographics, patient and procedure related risk factors, and follow-up data were recorded on standardized case report forms by the study coordinator at each site who was blinded to allocation assignments of the patients. All data were subsequently entered into REDCap, which was monitored on a weekly basis for completeness and accuracy.

Fluid administration
--------------------

Data regarding fluid administration during and after ERCP were collected on all patients in prospective observational manner. Periprocedural fluid was defined as the fluid infused during ERCP in the endoscopy suit and after ERCP in the post-anesthesia care unit (PACU) for up to 6 hours. The volume and type of periprocedural fluid(s) administered was recorded by the study coordinator, while the patient was in the endoscopy suite and/or PACU. Fluid administration was not determined *a priori* or controlled for in the INDIEH trial. The use, type and volume of fluid administered was left to the the discretion of the endoscopist, anesthesiologist and/or clinicians in the endoscopy suite and /or PACU.

Study outcomes
--------------

The primary outcome of interest was an evaluation of the impact of volume and type of fluid administration on the incidence of PEP. PEP was defined by the consensus guidelines as 1) New or increased abdominal pain that was clinically consistent with acute pancreatitis; 2) Amylase and/or lipase ≥ 3 × the upper limit of normal 24 hours after the procedure; and 3) Hospitalization or prolongation of existing hospitalization for at least 2 days [@JR1710-12] . The secondary outcome was to evaluate impact of fluid administration on the length of hospital stay after ERCP.

Adverse events
--------------

Complications related to ERCP or study interventions including bleeding, perforation and infection, acute renal failure, evidence of overt gastrointestinal bleeding, indomethacin allergy, hypertension and arrhythmias due to epinephrine were recorded as adverse events (AEs) [@JR1710-12] [@JR1710-13] [@JR1710-14] . AEs related to volume overload (development of peripheral edema, pulmonary rales, or ascites) were also recorded. All recorded AEs were reported to the local IRB at each site as well as the DSMB for the trial.

Statistical analysis
--------------------

Statistical analysis was performed using SPSS 25 statistical software package (IBM Analytics, Armonk, New York, United States). Categorical variables were assessed by univariable analysis using the Pearsonʼs Chi Square test or Fisherʼs exact tests as appropriate. Continuous variables were compared using studentʼs *t* test. Periprocedural fluid therapy and the type of periprocedural fluid(s) were evaluated for their impact on the incidence of PEP using multivariable regression analysis. Results were expressed as mean ± standard deviation (SD) and odds ratios ORs with the corresponding 95 % confidence intervals (CIs). A two-sided *P*  \< 0.05 was considered statistically significant. We used scatter plot to show the association between fluid administration and length of hospitalization and performed Pearson test for correlation. This study was registered with ClinicalTrials.gov, number NCT02116309 and data entry into the website was completed at the end of the study [@JR1710-15] .

Results
=======

Baseline characteristica
------------------------

A total of 960 patients were enrolled in the study from November 2014 to November 2016 (mean age: 52.33±14.96 years, 551 (57.4 %) females). Females \< 50 years of age (25.4 %) and difficult cannulation (84.9 %) were the most common patient and procedural risk factors, respectively. Trainees were involved in 24 % of the cases.

Fluid administration
--------------------

A total of 476 (49.6 %) patients received periprocedural fluids ( [Fig. 1](#FI1710-1){ref-type="fig"} ). The type of fluid included normal saline (NS), dextrose 5 % (D5) and lactated Ringerʼs (LR). Among the patients who received periprocedural fluids, the volume ranged from 100 mL to 3000 mL with a mean of 1245 mL (±629). There were 174 patients (37 %) who received lactated Ringerʼs (LR) with a mean of 588 mL (±315). Patients who were female, whose procedures involved trainees, who were inpatients and who have had a history of post-ERCP pancreatitis received more fluid ( [Table 1](#TB1710-1){ref-type="table"} ).

![ Flowchart demonstrating risk of post-ERCP pancreatitis in individual hydration categories (PEP = post-ERCP pancreatitis).](10-1055-a-1149-1359-i1710ei1){#FI1710-1}

###### Comparison of baseline characteristics and procedural maneuvers between patients who did and did not receive periprocedural fluids.

  Patient and procedural characteristics                                    No periprocedural fluids (n = 484)   Received periprocedural fluids (n = 476)   *P* value
  ------------------------------------------------------------------------- ------------------------------------ ------------------------------------------ -----------
  Age -- year ± S.D.                                                         53.3 ± 15.8                          51.4 ± 14                                 0.05
  Female gender -- n (%)                                                    250 (51.7 %)                         298 (63.1 %)                                \< 0.001
  Inpatient status -- n (%)                                                 102 (21.1 %)                         182 (38.2 %)                                \< 0.001
  Clinical suspicion of sphincter of Oddi dysfunction (Type1 /2) -- n (%)     7 (1.4 %)                            8 (1.8 %)                                0.76
  History of recurrent pancreatitis -- n (%)                                  4 (0.8 %)                           12 (2.5 %)                                0.05
  History of post-ERCP pancreatitis -- n (%)                                  0 (0 %)                              6 (1.3 %)                                0.01
  Difficult cannulation (\> 5 attempts) -- n (%)                            417 (86.2 %)                         394 (83.5 %)                               0.25
  Precut sphincterotomy -- n (%)                                            109 (22.5 %)                          89 (18.9 %)                               0.41
  Pancreatography -- n (%)                                                    4 (0.8 %)                            8 (1.7 %)                                0.26
  Pancreatic sphincterotomy -- n (%)                                          6 (1.2 %)                            9 (1.9 %)                                0.45
  Pancreatic acinarization -- n (%)                                           0 (0 %)                              2 (0.4 %)                                0.24
  Trainee involvement -- n (%)                                               33 (6.8 %)                          196 (41.5 %)                                \< 0.001
  Topical spray of epinephrine -- n (%)                                     248 (51.2 %)                         227 (48.1 %)                               0.35

ERCP, endoscopic retrograde cholangiopancreatography

Study outcomes
--------------

### Volume of fluid

There was a trend towards a lower incidence of PEP among patients who received periprocedural fluid compared to those who did not receive periprocedural fluid (5.2 % (n = 25) vs 8.0 % (n = 38), *P*  = 0.079; OR: 0.65; 95 % CI 0.38--1.09). Among the 476 patients who received fluids, those who developed PEP received a lower mean volume of fluid (752±783 mL) compared to those who did not develop PEP (1012±725 mL), ( *P*  = 0.036). The distribution of volume of fluid across these two groups is depicted as a waterfall plot ( [Fig. 2](#FI1710-2){ref-type="fig"} ). On the multivariable analysis, after adjusting for all significant variables found on univariable analysis, periprocedural fluids did not significantly impact the incidence of PEP. There was a reduction in the length of hospital stay as the volume of periprocedural fluid administration increased (r = 0.16, *P*  \< 0.001) ( [Fig. 3](#FI1710-3){ref-type="fig"} ).

![ Waterfall plot displaying the volume of fluid received by patients who developed post-ERCP pancreatitis (PEP) (black bars) and those who did not develop PEP (grey bars).](10-1055-a-1149-1359-i1710ei2){#FI1710-2}

![ Scatter plot displaying the volume of fluid received by patients in relation to length of hospital stay.](10-1055-a-1149-1359-i1710ei3){#FI1710-3}

### Type of fluid

Patients who developed PEP received a lower volume of LR compared to those who did not develop PEP (329 ± 356 mL vs. 570 ± 559 mL, *P*  = 0.006). This was, however, not significant on multivariable analysis when adjusted for all variables found significant on univariable analysis. There was a lower trend of PEP among patients who received LR compared to those who received all other fluid types (OR, 0.56; 95 % CI 0.31--0.99).

### Adverse events

There were no reports of perforation, infection, myocardial infarction, cerebrovascular accident, acute renal failure or allergic reaction. Potentially attributable adverse events to the study interventions such as post-procedure hypertension (7.05 % vs 7.33 %, *P*  = 0.59), post-sphincterotomy bleeding (0 vs 0.2 %, *P*  = 0.36), arrhythmia after ERCP (0.2 % vs 0, *P*  = 0.36) were not significantly different between the indomethacin alone and combination groups, respectively. The overall mortality was 0.6 % and this was unrelated to the primary outcome. There were 6 deaths evenly distributed between the indomethacin alone and combination groups. Four of the deaths were due to metastatic cholangiocarcinoma and two deaths were due to decompensated cirrhosis.

Discussion
==========

We found that higher mean volumes of IV fluid and use of lactated Ringerʼs solution was associated with a lower risk of PEP in a secondary analysis of an international multicenter PEP prevention trial in high risk patients. We also found that patients who received increased volumes of fluid had a shorter length of hospital stay.

A few retrospective studies initially showed that higher periprocedural fluid volumes reduce the length of hospital stay after ERCP [@JR1710-6] [@JR1710-16] . Buxbaum et al. conducted the first RCT showing that aggressive hydration is beneficial for preventing PEP in average risk patients [@JR1710-7] . However, this was a pilot study which included only inpatients and was underpowered. Two relatively larger subsequent RCTs showed similar results [@JR1710-8] [@JR1710-17] . The previous RCTs administered fluids in patients over 8 hours after ERCP which is a longer PACU recovery period than usual when compared to most centers around the world [@JR1710-7] [@JR1710-8] . The current multicenter FLUYT trial from the Netherlands has a similar limitation as fluids are administered over 8 hours after ERCP [@JR1710-18] . The results of our study are; therefore, more clinically generalizable across global endoscopic practice as we recorded fluids administered to patients during usual recovery times after ERCP.

Our study further showed that aggressive resuscitation with lactated Ringerʼs (LR) might lead to a lower incidence of PEP in high-risk patients as compared to administration of other fluid types. This has been supported by previous retrospective as well as prospective studies in average and high risk patients [@JR1710-7] [@JR1710-8] [@JR1710-17] . Mok et el. showed that the combination of LR and indomethacin reduces the risk of PEP from 21 % to 6 % in high-risk patients, when compared to a combination of normal saline and placebo [@JR1710-9] . However, the two by two factorial design of this trial included a placebo arm where normal saline and a placebo suppository were administered to high-risk patients which raises ethical concerns as rectal nonsteroidal anti-inflammatory drug administration has become a common clinical practice for the prevention of PEP in high-risk patients. A clinically more pragmatic trial design would have compared the combination of LR and rectal indomethacin to rectal indomethacin alone. Nonetheless, the trial by Mok found a comparable incidence of PEP in the arm of the study where the combination of indomethacin and LR were administered when compared to the present study. An important downside to the use of large volumes of NS in patients with acute pancreatitis is the development of hyperchloremic acidosis that favors the inflammatory cascade as compared to LR which directly inhibits macrophages involved in inflammation [@JR1710-19] [@JR1710-20] . Because LR is widely available, safe, and inexpensive and fluids are universally administered to patients undergoing ERCP, infusion of LR represents a simple and convenient option for the prevention of PEP [@JR1710-21] .

Our study has several strengths. This is the largest prospective study to date evaluating the effect of fluid administration during and after ERCP in high risk patients using the results of a large multi-center, international randomized controlled trial. As mentioned previously, the results of our study are more generalizable as fluid administration was recorded during the recovery period that would be most commonly observed in outpatients undergoing ERCP. Moreover, half of our patients did not receive any fluids which reflects clinical practice in many countries around the world. Given the trend towards lower PEP rates in patients receiving fluids compared to no fluid administration, our study will hopefully urge more centers around the world to consider incorporating the use of fluids in high risk patients undergoing ERCP. All the risk factors for PEP were adequately represented in our study cohort [@JR1710-10] . We also excluded SOD Type 3 patients, which increases the clinical generalizability of our study in the post-EPISOD era as compared to the Mok trial where approximately 20 % of patients had SOD.

However, there were several limitations. Our results were not significant on multivariable analysis when adjusted for patient and procedural characteristics which may be due to multiple reasons. First, our patients were not randomized on a priori basis to any specific type or volume of IV fluids as much of the literature supporting fluid administration in patients undergoing ERCP was published after the initiation of our trial. Second, our sample size was not powered to show the independent effect of fluid type and volume on the incidence of PEP. There was a wide range of IV fluid volumes administered which reduces the generalizability of the current study but this may also reflect different fluid administration practices across different centers and countries, thereby providing pragmatic evidence for endoscopists in clinical settings. For example, inpatients were more likely to receive periprocedural fluids compared to those undergoing ERCP on an outpatient basis.

Conclusion
==========

In conclusion, higher volumes of fluid and LR were associated with further reduction in incidence of post-ERCP pancreatitis and length of hospital stay beyond rectal indomethacin based on this subgroup analysis of a PEP prophylaxis trial of high-risk patients. This analysis was limited due to heterogeneity in the volume of fluid administered since the fluid type or volume was not controlled for in the initial trial. Further adequately powered RCTs are needed to evaluate the effect of type and volume of periprocedural fluids on the development of PEP.
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